Melfalan Sun (Melphalan)

Melphalan belongs to the nitrogen‑mustard class of alkylating agents. It binds to DNA bases and creates cross‑links that prevent the DNA strands from separating, thereby blocking replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells.

The specific dose of melphalan is individualized for each patient based on factors such as cancer type, disease stage, body surface area, kidney function and prior therapies. The prescribing oncologist determines the appropriate amount and schedule; no standard dose can be stated without a medical assessment.

Melphalan is classified as contraindicated in pregnancy because it can cross the placenta and cause fetal harm, including birth defects or miscarriage. It is also excreted in breast milk and may affect a nursing infant. Use is only considered if the potential benefit to the mother outweighs the risk to the child, and only under strict medical supervision.

To request Melfalan Sun, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Melphalan is an alkylating agent, similar to cyclophosphamide and ifosfamide, but it is often chosen for its activity against multiple myeloma and certain solid tumors. Compared with newer targeted therapies, melphalan has a broader cytotoxic profile but may cause more myelosuppression. Choice of therapy depends on disease characteristics, prior treatment history and patient tolerance.

Melfalan Sun vials should be stored at ambient temperature, below 25 °C, in their original packaging to protect from light and moisture. Do not freeze the product. Before preparation, inspect the vial for particulate matter or discoloration, and handle using aseptic technique in a controlled environment.

Melfalan Sun is given by intravenous infusion. The drug is diluted in an appropriate carrier solution and administered over a period determined by the treating physician, usually ranging from a few minutes to several hours, depending on the dose and patient tolerance.

The most serious risks include secondary malignancies such as therapy‑related leukemia, severe infections due to profound neutropenia, and rare pulmonary toxicity like interstitial pneumonitis or fibrosis. Patients should be monitored closely for signs of infection, respiratory symptoms and any unexpected hematologic changes.

Melphalan should be avoided in patients with known hypersensitivity to nitrogen‑mustard agents, in those with severe bone‑marrow failure, uncontrolled infections, or significant renal or hepatic impairment that cannot be corrected. Pregnant or breastfeeding women should not receive the drug unless the potential benefit justifies the risk.